Kiora Pharmaceuticals Inc (KPRX): Total Assets
$24.25M
As of 2025-12-31
$23.78M
As of 2026-06-30
+9.1%
3-year compound annual growth
+9.6%
5-year compound annual growth
+9.8%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $24.25M | -33.5% | 2026-03-25, Balance as of period end |
| 2024-12-31 | $36.48M | +166.1% | 2026-03-25, Balance as of period end |
| 2023-12-31 | $13.71M | -26.6% | 2025-03-25, Balance as of period end |
| 2022-12-31 | $18.68M | -7.2% | 2024-03-25, Balance as of period end |
| 2021-12-31 | $20.13M | +31.5% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $15.30M | +51.3% | 2022-07-07, Balance as of period end |
| 2019-12-31 | $10.11M | -29.2% | 2021-03-25, Balance as of period end |
| 2018-12-31 | $14.28M | -0.2% | 2020-03-04, Balance as of period end |
| 2017-12-31 | $14.31M | +47.0% | 2019-03-01, Balance as of period end |
| 2016-12-31 | $9.73M | +2.3% | 2018-03-02, Balance as of period end |
| 2015-12-31 | $9.51M | +576.0% | 2017-02-23, Balance as of period end |
| 2014-12-31 | $1.41M | n/a | 2016-03-30, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Kiora Pharmaceuticals Inc (KPRX) | 2025-12-31 | $24.25M | -33.5% |
| Abbott Laboratories (ABT) | 2025-12-31 | $86.71B | +6.5% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $90.04B | -2.8% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $37.66M | -3.0% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $112.48B | +42.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $208.16B | -2.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $199.21B | +10.6% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $261.15M | +8.4% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $136.87B | +16.9% |
Compare KPRX, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗